11
total announcements
544449.BO · 15 min delayed
Anthem Biosciences Ltd
Anthem Biosciences Ltd announced its Q1 FY27 results, with consolidated revenues from operations at Rs. 418 crores, EBITDA at Rs. 176 crores, and PAT at Rs. 120 crores. The company reported a net cash position of Rs. 1,720 crores as of June 30, 2026.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has submitted the voting results and a copy of the scrutinizer report of the 20th Annual General Meeting held on July 22, 2026. All resolutions were passed with a requisite majority.
Anthem Biosciences Ltd
Anthem Biosciences Limited held its 20th Annual General Meeting (AGM) on July 22, 2026, through video conferencing. The meeting was conducted in compliance with applicable laws and regulations. The AGM transacted various businesses, including the adoption of audited financial statements, declaration of dividend, appointment of statutory auditors, and approval of related party transactions. The meeting was attended by the company's directors, statutory auditors, and internal auditors, and was conducted through remote e-voting.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has made available the audio recording of its earnings call for the quarter ended June 30, 2026, on its website.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has published its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has revised its unaudited consolidated financial results for Q1FY27, with revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has revised its investor presentation for unaudited consolidated financial results for Q1FY27, showing a 22.6% YoY decline in revenue from operations to ₹4,182 Mn, with EBITDA margins at 39.6% and PAT margins at 27.1%. The company's net cash position as of June 30, 2026, is ₹17,197 Mn.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has announced its unaudited consolidated financial results for Q1FY27, with revenue from operations at ₹4,182 Mn, EBITDA at ₹1,755 Mn, and PAT at ₹1,199 Mn. The company's net cash position as of June 30, 2026, is ₹17,197 Mn.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors and reviewed by the Audit Committee.
Anthem Biosciences Ltd
Anthem Biosciences Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The results will be published in newspapers and are available on the company's website.